Teva EVP McAvoy reports purchase of 1,113 TEVA shares on Form 4

Rhea-AI Filing Summary

David R. McAvoy, identified as an Executive Vice President and Chief Legal Officer of Teva Pharmaceutical Industries Ltd. (TEVA), reported an open-market purchase of 1,113 ordinary shares on 09/05/2025 at a price of $18.8572 per share. After the transaction McAvoy beneficially owns 13,027 ordinary shares. The filing notes that the ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.

The Form 4 was signed on behalf of McAvoy by an attorney-in-fact and filed under Section 16 reporting requirements. The report contains no other derivative transactions or additional disclosures.

Positive

• Insider purchase reported: David R. McAvoy acquired 1,113 shares, which may indicate insider confidence.
• Proper disclosure: Transaction reported on Form 4 with attorney-in-fact signature and ADS representation note.

Negative

• None.

Insights

Securities Analyst

TL;DR: An insider purchased 1,113 shares at $18.8572, modestly increasing beneficial ownership to 13,027 shares.

The transaction is a straightforward open-market purchase reported on Form 4. The size of the purchase is small relative to a public company’s outstanding shares, so it is unlikely to be material to Teva’s valuation by itself. However, insider buying can signal personal conviction. The filing is complete for the non-derivative trade and includes the customary note about ADS representation.

Corporate Governance Expert

TL;DR: Officer and director-level insider executed a routine purchase; filing properly reported by attorney-in-fact.

From a governance standpoint, the form discloses the reporter’s role (EVP, Chief Legal Officer) and the post-transaction ownership level, meeting Section 16 disclosure norms. The signature by an attorney-in-fact is acceptable and commonly used. There are no indications of related-party transactions or derivative activity in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McAvoy David R.

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A STREET

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	09/05/2025		P		1,113	A	$18.8572	13,027	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

	/s/ Dov Bergwerk as attorney-in-fact for David R. McAvoy	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did David R. McAvoy report on Form 4 for TEVA?

The Form 4 reports an open-market purchase of 1,113 ordinary shares on 09/05/2025 at $18.8572 per share.

How many TEVA shares does David R. McAvoy beneficially own after the transaction?

After the reported purchase McAvoy beneficially owns 13,027 ordinary shares.

What is David R. McAvoy's role at TEVA as listed on the Form 4?

He is reported as an Executive Vice President, Chief Legal Officer and is also identified with the director/10% owner checkbox as applicable.

When was the Form 4 transaction dated and when was the form signed?

The transaction date is 09/05/2025 and the form was signed by an attorney-in-fact on 09/09/2025.

Were any derivative securities reported in this Form 4?

No. The filing includes only a non-derivative purchase of ordinary shares and shows no derivative transactions.